



# **OPEN ACCESS**

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

\*CORRESPONDENCE
Ling Liu,

☑ anddymar@sina.com
Zhan Lin,
☑ linzhann977@163.com

<sup>†</sup>These authors contributed equally to this work and share first authorship

# SPECIALTY SECTION

This article was submitted to *Cancer* Genetics and Oncogenomics, a section of the journal Frontiers in Genetics

RECEIVED 17 January 2023 ACCEPTED 18 January 2023 PUBLISHED 25 January 2023

### CITATION

Yang Y, Ye X, Zhang H, Lin Z, Fang M, Wang J, Yu Y, Hua X, Huang H, Xu W, Liu L and Lin Z (2023), Corrigendum: A Novel transcription factor-based signature to predict prognosis and therapeutic response of hepatocellular carcinoma. *Front. Genet.* 14:1146199. doi: 10.3389/fgene.2023.1146199

# COPYRIGHT

© 2023 Yang, Ye, Zhang, Lin, Fang, Wang, Yu, Hua, Huang, Xu, Liu and Lin. This is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Corrigendum: A Novel transcription factor-based signature to predict prognosis and therapeutic response of hepatocellular carcinoma

Yanbing Yang<sup>1†</sup>, Xuenian Ye<sup>2†</sup>, Haibin Zhang<sup>2</sup>, Zhaowang Lin<sup>1</sup>, Min Fang<sup>1</sup>, Jian Wang<sup>1</sup>, Yuyan Yu<sup>1</sup>, Xuwen Hua<sup>1</sup>, Hongxuan Huang<sup>2</sup>, Weifeng Xu<sup>3</sup>, Ling Liu<sup>4\*</sup> and Zhan Lin<sup>1\*</sup>

<sup>1</sup>Department of Radiology, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China, <sup>2</sup>Department of Orthopedics, Dongguan People's Hospital, Dongguan, China, <sup>3</sup>Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China, <sup>4</sup>Department of Radiology, The First Affiliated Hospital of Dali University, Dali, China

# KEYWORDS

transcription factor, high mobility group AT-hook protein 1, MAF BZIP transcription factor G, prognosis, therapeutic response, hepatocellular carcinoma

# A Corrigendum on

A Novel transcription factor-based signature to predict prognosis and therapeutic response of hepatocellular carcinoma

by Yang Y, Ye X, Zhang H, Lin Z, Fang M, Wang J, Yu Y, Hua X, Huang H, Xu W, Liu L and Lin Z (2023). Front. Genet. 13:1068837. doi: 10.3389/fgene.2022.1068837

In the original article, there was a mistake in the **Funding** statement as published. The correct grant number for the Startup Fund for Scientific Research of Fujian Medical University is 2018QH1202. Corrected funding statement is given below:

"This work was supported by the Scientific Research Project for the Middle-aged and Youths of Fuzhou Health Department (grant number: 2019-S-wq9) and the Startup Fund for Scientific Research of Fujian Medical University (grant number: 2018QH1202)."

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

# Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.